ARES

Ares Real Estate Announces Acquisition of Hotel Portfolio from Landsec

Retrieved on: 
Jeudi, mai 9, 2024
Asset Management, Professional Services, Finance, Landsec, Ares, Geography, Carbon footprint, COVID-19, Senior, ARES, Acquisition, EQ, Commercial property

Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced today that funds managed by Ares Real Estate have acquired a hotel portfolio from Landsec alongside hotel operating partner EQ Group (“EQ”), a leading European hospitality investment and management platform.

Key Points: 
  • Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced today that funds managed by Ares Real Estate have acquired a hotel portfolio from Landsec alongside hotel operating partner EQ Group (“EQ”), a leading European hospitality investment and management platform.
  • In parallel with the closing of the acquisition, Ares entered into an agreement with AccorInvest to surrender these leases and transfer operations of the relevant hotels to Ares.
  • “This transaction highlights our ability to create solutions which unlock assets in today’s dislocated market,” said John Ruane, Partner and Co-Head of Ares European Real Estate.
  • In Europe, Ares Real Estate has a tenured, local team of approximately 70 real estate investment professionals and a track record spanning approximately three decades of operations.

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

Retrieved on: 
Mardi, mai 7, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EAP, Cancer, MET, Congress, Safety, Haematopoietic system, Survival, Institut Gustave Roussy, Maat, Partnership, Trial of the century, Artificial intelligence, AP-HP, DSMB, ICI, IGR, PICASSO, Rated R, Patient, ARES, Doctor of Pharmacy, D28, INRAE, Lung, EBMT, ALS, AACR, NSCLC, Lung cancer, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.
  • Hervé Affagard, CEO and co-founder of MaaT Pharma said: “We're confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders.
  • This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.
  • The related costs for MaaT Pharma are limited to clinical product supply in line with previous cash projections.

Ares Management Corporation Reports First Quarter 2024 Results

Retrieved on: 
Jeudi, mai 2, 2024
Asset Management, Professional Services, Finance, Webcast, Dividend, ID, International, Home, ARES, Telephone, GAAP, Growth, Eastern Time Zone, Holding company

Ares Management Corporation (NYSE:ARES) today reported its financial results for its first quarter ended March 31, 2024.

Key Points: 
  • Ares Management Corporation (NYSE:ARES) today reported its financial results for its first quarter ended March 31, 2024.
  • GAAP net income attributable to Ares Management Corporation was $73.0 million for the quarter ended March 31, 2024.
  • On a basic and diluted basis, net income attributable to Ares Management Corporation per share of Class A and non-voting common stock was $0.33 for the quarter ended March 31, 2024.
  • The presentation is titled “First Quarter 2024 Earnings Presentation.”
    Ares will host a conference call on May 2, 2024 at 11:00 a.m. (Eastern Time) to discuss first quarter results.

MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

Retrieved on: 
Lundi, avril 15, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, FDA, EAP, Cancer, MET, Hospital, Hematology, Food, Sorbonne University, Survival, Orphan, OS, DSMB, Disease, Rated R, Patient, ARES, D28, EMA, Symantec Endpoint Protection, Hematopoietic stem cell transplantation, EBMT, Toxicity, European Medicines Agency, Data monitoring committee, Pharmaceutical industry

Prof. Malard commented: “MaaT013 shows remarkable efficacy at 18 months, yielding more complete responses in aGvHD patients who have shown resistance to current treatments, as compared to other available therapies.

Key Points: 
  • Prof. Malard commented: “MaaT013 shows remarkable efficacy at 18 months, yielding more complete responses in aGvHD patients who have shown resistance to current treatments, as compared to other available therapies.
  • Notably, these results are achieved with just 3 doses in less than 2 weeks of treatment initiation.
  • The data presented highlights the strong safety profile of MaaT013 (full details here ) and translates into increased OS.
  • MaaT Pharma also presented its ongoing Phase 2b trial design for MaaT033 developed as an adjunctive therapy to enhance OS in allogeneic hematopoietic stem cell transplantation.

New Product Release: An AI-driven Weapon to Fight Vehicle-Associated Crime and Terrorism

Retrieved on: 
Mardi, avril 9, 2024
Law enforcement, Death, PlateSmart, Research, Transport, Human, Life, ARES, Crime, Terrorism, ALPR, Automatic number-plate recognition, LPR

OLDSMAR, Fla., April 9, 2024 /PRNewswire-PRWeb/ -- Florida-based PlateSmart Technologies gets ready to launch its new product that will deliver to officers a greater real-time understanding of crime scenes.

Key Points: 
  • OLDSMAR, Fla., April 9, 2024 /PRNewswire-PRWeb/ -- Florida-based PlateSmart Technologies gets ready to launch its new product that will deliver to officers a greater real-time understanding of crime scenes.
  • It works to solve crime, to prevent crime, and to keep you safe," said Stephen A. Zappala, Jr., District Attorney of Allegheny County, Pennsylvania.
  • With the global vehicle population reaching unprecedented numbers, the demand for increasingly sophisticated and reliable security systems has never been higher.
  • It works to solve crime, to prevent crime, and to keep you safe," said Stephen A. Zappala, Jr., District Attorney of Allegheny County, Pennsylvania.

MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview

Retrieved on: 
Jeudi, mars 28, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, AP-HP, Bone marrow, Survival, Immunotherapy, Patient, Innovation, IND, Ipilimumab, European Medicines Agency, Therapy, Artificial intelligence, Charcot disease, ASH, EMA, Head, MET, Investigational New Drug, Nivolumab, Safety, SITC, Microbiome, Food, ODD, Development, Acceleration, Maat, ARES, Cancer, AACR, DSMB, Haematopoietic system, Annual general meeting, OS, EUR, Physician, CIMON, CGMP, EAP, EBMT, ICI, Society, Randomized controlled trial, Symantec Endpoint Protection, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.
  • In December 2023 , the Company presented positive results from the Early Access Program (EAP) in Europe involving 111 patients with aGvHD treated with MaaT013, at the 2023 American Society of Hematology (ASH) Annual Meeting.
  • In April 2023 , data from the Phase 1b study (CIMON) with MaaT033, previously communicated during the 64th annual ASH meeting, were also presented at the EBMT 2023 conference.
  • During 2023 and Q1 2024, MaaT Pharma reinforced its board of directors, executive team, and key functions:
    Karim Dabbagh as Chairman and Nadia Kamal as Director, both independent.

MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

Retrieved on: 
Mardi, mars 12, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Rated R, Toxicity, Survival, ASH, Hematology, Risk, Patient, Hospital, ARES, EAP, Policy, Cancer, Quality of life, MET, DSMB, D28, Pharmaceutical industry

Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy.

Key Points: 
  • Details from the presentation will be disclosed in a press release on April 17th, 2024, in compliance with the conference embargo policy.
  • Aligned with its mission to enhance the survival of cancer patients, MaaT Pharma has been actively involved in the EAP in Europe since 2019.
  • The Company has consistently presented real-world data from its EAP at major hematology conferences over the past four years.
  • To date, over 220 patients have been treated with MaaT013 in Europe in clinical trials and the EAP.

Ares Management Launches Ansley Park Capital

Retrieved on: 
Lundi, mars 4, 2024
Professional Services, Finance, GE Capital, Capital market, Marketing, Health, Global health, Ares, Risk, City National Bank, Wells Fargo, ARES, Credit, Partnership, Management

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that funds managed by its Alternative Credit strategy (“Ares Alternative Credit”) have launched Ansley Park Capital (“Ansley Park”), a newly-formed lending and specialty finance company that delivers full spectrum, customized financing solutions for essential-use, large-ticket equipment.

Key Points: 
  • Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that funds managed by its Alternative Credit strategy (“Ares Alternative Credit”) have launched Ansley Park Capital (“Ansley Park”), a newly-formed lending and specialty finance company that delivers full spectrum, customized financing solutions for essential-use, large-ticket equipment.
  • “We are excited to launch Ansley Park together with this talented and experienced team,” said Joel Holsinger, Partner and Co-Head of Ares Alternative Credit.
  • “The equipment finance landscape is rapidly evolving, and the team’s deep industry expertise across a wide range of asset classes will enable Ansley Park to effectively deploy capital critical to supporting the financing needs of companies driving the U.S. economy.”
    He added, “In addition to direct financing originations, Ansley Park is uniquely positioned to partner with banks in executing capital markets transactions, acquire equipment finance portfolios, develop structured flow programs and design equipment-focused balance sheet optimization and capital relief solutions.”
    “We are thrilled to announce the establishment of Ansley Park through our partnership with Ares,” said Eric Miller, President & Chief Executive Officer of Ansley Park.
  • Aligning Ares' investment activities with its societal impact, Ares and Ares Alternative Credit portfolio managers have committed to donate a portion of the performance fees from Ares Alternative Credit flagship funds to support global health and education charities.

Ares Management Special Opportunities Team to Join its Global Credit Group

Retrieved on: 
Lundi, février 26, 2024
Asset Management, Professional Services, Finance, Equity (finance), Growth, Ares, ARES, Financial services

Ares Management Corporation (NYSE: ARES) today announced that its Special Opportunities strategy, currently a business within its Private Equity Group, will be joining the firm’s Credit Group and will be named Opportunistic Credit.

Key Points: 
  • Ares Management Corporation (NYSE: ARES) today announced that its Special Opportunities strategy, currently a business within its Private Equity Group, will be joining the firm’s Credit Group and will be named Opportunistic Credit.
  • Moving the strategy to the Credit Group is expected to enable greater collaboration across the Ares platform, enhancing benefits to Ares’ limited partners, sponsor partners and portfolio companies.
  • The Opportunistic Credit team will build on the accomplishments of the Special Opportunities strategy and leverage the experience and broad direct origination network across the firm’s leading global Credit platform.
  • The Opportunistic Credit strategy will be reflected within the Ares Credit Group in Ares’ public reporting, effective March 31, 2024.

ARES Security Corporation Awarded Contract for Next Generation Security Computer and Video Management System

Retrieved on: 
Mardi, mars 5, 2024
Engineering design process, ATAK, Partnership, Safety, High availability, Palisades Nuclear Generating Station, Critical infrastructure, AVERT, Senior, Holtec International, ARES, Physical security, Robotics, Environment, SDVOSB

ARES and ShadowTech Labs both service the needs of the Department of Defense, Department of Energy, Nuclear Regulatory Commission, and Critical Infrastructure facilities worldwide.

Key Points: 
  • ARES and ShadowTech Labs both service the needs of the Department of Defense, Department of Energy, Nuclear Regulatory Commission, and Critical Infrastructure facilities worldwide.
  • ARES and ShadowTech will deploy ARES Safety Act Certified, AVERT C2SIM solution at Palisades.
  • AVERT C2SIM is the next generation security platform, enabling seamless implementation of any camera, sensor, video management and access control system with a High Availability architecture and environment.
  • ShadowTech provides the highest level of expertise in Engineering Design, System Integration, Cyber Security, testing and deployment of Commercial Nuclear security systems.